Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

Leuk Lymphoma. 2021 Feb;62(2):330-336. doi: 10.1080/10428194.2020.1827241. Epub 2020 Oct 7.


We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan-Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study - the second largest real-world cohort reported to date - underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile.

Keywords: Pralatrexate; T-cell lymphoma; cutaneous T-cell lymphoma; mucositis; peripheral T-cell lymphoma.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Aminopterin / analogs & derivatives
  • Australia / epidemiology
  • Humans
  • Lymphoma, T-Cell* / drug therapy
  • Neoplasm Recurrence, Local* / drug therapy
  • Retrospective Studies
  • Treatment Outcome


  • 10-propargyl-10-deazaaminopterin
  • Aminopterin